arrow_back Back to App

Biosimilar Education: Better Information for Patients and Healthcare Providers.

This new law aims to increase knowledge about biosimilar medications among patients, caregivers, and healthcare professionals. This will enable citizens to better understand their treatment options and make informed health decisions, potentially impacting drug accessibility and costs.
Key points
An internet website will be created to provide educational materials on biosimilar products, explaining key terms and usage guidelines.
Healthcare providers will gain access to continuing education programs to better prescribe and understand biosimilar medications.
Information on reporting adverse events for biosimilar products will be more readily available to everyone.
article Official text account_balance Process page
VOTING RESULTS
2021-04-14
98%
For 412
Against 8
Abstain 0
Full voting results open_in_new
Became Law
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_164
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
Process start date: 2021-02-02
Voting date: 2021-04-14
Meeting no: 1
Voting no: 101
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Advancing Education on Biosimilars Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_164.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-02.

What are the main provisions?

Key points include:

  • An internet website will be created to provide educational materials on biosimilar products, explaining key terms and usage guidelines.
  • Healthcare providers will gain access to continuing education programs to better prescribe and understand biosimilar medications.
  • Information on reporting adverse events for biosimilar products will be more readily available to everyone.
What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Sen. Hassan, Margaret Wood [D-NH].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-8.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health